Literature DB >> 20494704

Transarterial liver-directed therapies of neuroendocrine hepatic metastases.

Javier Nazario1, Sanjay Gupta.   

Abstract

Neuroendocrine tumors (NETs) comprise a diverse group of slowly growing tumors with an indolent course, characterized by the capacity to synthesize and secrete polypeptide products that are hormonally active. Presence of liver metastases results in significant debilitating hormonal symptoms, and is associated with poor prognosis. Systemic chemotherapy has limited success in the management of patients with NET hepatic metastases. Although somatostatin analogs are effective in controlling symptoms in many of these patients, the disease can become refractory to treatment. For these reasons, interventional radiologic techniques for liver-directed therapy have become an important treatment option in patients with metastatic NETs. Transcatheter arterial procedures such as transarterial embolization (TAE), transarterial chemoembolization (TACE), and selective internal radiation therapy (SIRT) have been shown to reduce hormone levels, palliate symptoms, and reduce the tumor burden in many patients with unresectable and symptomatic NET hepatic metastases. This article summarizes the most recent information on arterial-based liver-directed therapies in the treatment of metastatic NETs. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20494704     DOI: 10.1053/j.seminoncol.2010.03.004

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  19 in total

Review 1.  Pancreatic neuroendocrine tumors.

Authors:  Shailesh V Shrikhande; Bhawna Sirohi; Mahesh Goel; Savio G Barreto
Journal:  Indian J Gastroenterol       Date:  2012-10-03

Review 2.  Carcinoid Syndrome: Updates and Review of Current Therapy.

Authors:  Kira Oleinikov; Shani Avniel-Polak; David J Gross; Simona Grozinsky-Glasberg
Journal:  Curr Treat Options Oncol       Date:  2019-07-09

3.  Transarterial embolization (TAE) is equally effective and slightly safer than transarterial chemoembolization (TACE) to manage liver metastases in neuroendocrine tumors.

Authors:  Francesco Fiore; Michela Del Prete; Renato Franco; Vincenzo Marotta; Valeria Ramundo; Francesca Marciello; Antonella Di Sarno; Anna Chiara Carratù; Chiara de Luca di Roseto; Annamaria Colao; Antongiulio Faggiano
Journal:  Endocrine       Date:  2014-01-03       Impact factor: 3.633

4.  Embolization of metastatic neuroendocrine tumor resulting in clinical manifestations of syndrome of inappropriate secretion of antidiuretic hormone.

Authors:  Hooman Yarmohammadi; Joseph P Erinjeri; Karen T Brown
Journal:  J Vasc Interv Radiol       Date:  2015-04       Impact factor: 3.464

5.  Multimodal imaging for early functional response assessment of (90)Y-/ (177)Lu-DOTATOC peptide receptor targeted radiotherapy with DW-MRI and (68)Ga-DOTATOC-PET/CT.

Authors:  Sarah Wulfert; Clemens Kratochwil; Peter L Choyke; Ali Afshar-Oromieh; Walter Mier; Hans-Ulrich Kauczor; Jens-Peter Schenk; Uwe Haberkorn; Frederik L Giesel
Journal:  Mol Imaging Biol       Date:  2014-08       Impact factor: 3.488

6.  Pattern of retained contrast on immediate postprocedure computed tomography (CT) after particle embolization of liver tumors predicts subsequent treatment response.

Authors:  Xiaodong Wang; Joseph P Erinjeri; Xiaoyu Jia; Mithat Gonen; Karen T Brown; Constantinos T Sofocleous; George I Getrajdman; Lynn A Brody; Raymond H Thornton; Majid Maybody; Ann M Covey; Robert H Siegelbaum; William Alago; Stephen B Solomon
Journal:  Cardiovasc Intervent Radiol       Date:  2012-11-14       Impact factor: 2.740

Review 7.  Therapy of metastatic pancreatic neuroendocrine tumors (pNETs): recent insights and advances.

Authors:  Tetsuhide Ito; Hisato Igarashi; Robert T Jensen
Journal:  J Gastroenterol       Date:  2012-08-11       Impact factor: 7.527

8.  Comparison of transarterial liver-directed therapies for low-grade metastatic neuroendocrine tumors in a single institution.

Authors:  Eric S Engelman; Roberto Leon-Ferre; Boris G Naraev; Nancy Sharma; Shiliang Sun; Thomas M O'Dorisio; James Howe; Anna Button; Gideon Zamba; Thorvardur R Halfdanarson
Journal:  Pancreas       Date:  2014-03       Impact factor: 3.327

Review 9.  Pharmacotherapy of Zollinger-Ellison syndrome.

Authors:  Tetsuhide Ito; Hisato Igarashi; Hirotsugu Uehara; Robert T Jensen
Journal:  Expert Opin Pharmacother       Date:  2013-01-30       Impact factor: 3.889

10.  Ki67 score as a potential predictor in the selection of liver-directed therapies for metastatic neuroendocrine tumors: a single institutional experience.

Authors:  Smit Singla; Charles M LeVea; Venkata K Pokuri; Kristopher M Attwood; Michael M Wach; Garin M Tomaszewski; Boris Kuvshinoff; Renuka Iyer
Journal:  J Gastrointest Oncol       Date:  2016-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.